Privacy·Terms·Disclaimer

Bibliographic data courtesy of the U.S. National Library of Medicine (NLM), sourced from PubMed/MEDLINE.

SciRadar is not affiliated with, endorsed by, or sponsored by NLM or NCBI. Abstracts remain © their respective publishers.

Overall survival assessment in cancer drug trials: a luxury or a necessity? — SciRadar

Back to results

The Lancet. Oncology

Overall survival assessment in cancer drug trials: a luxury or a necessity?

Samuel X Stevens, Laure-Anne Teuwen, Bishal Gyawali

Published: 202510.1016/S1470-2045(25)00606-0

No abstract available for this study.